Abuse deterrent formulation technologies market is projected to grow at a healthy annualized rate of 16% till 2030, claims Roots Analysis

Published: August 2019


Advances in biotechnology and genome analysis have enabled the identification of several novel cancer biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, and to facilitate therapy related decisions

Roots Analysis has announced the addition of “Abuse Deterrent Formulation Technologies Market, 2019-2030” report to its list of offerings. 

Formulations that are capable of preventing an active pharmacological substance from being misused, offer a reliable way to limit the recreational / off-prescription drug use and its associated consequences. Several different types of abuse deterrent technologies have been developed in the last few years, which leverage either one or more of the following approaches to prevent abuse: physical / chemical barriers, agonist / antagonist combinations, aversive agents and prodrug format. 

To order this 280+ page report, which features 65+ figures and 90+ tables, please visit this link 

Key Market Insights 

Close to 60 abuse deterrent formulation technologies are currently available / under development 
Nearly half of the technologies that we came across are based on the physical / chemical barriers approach; these are followed by the technologies that use agonist / antagonist combinations (11%) and prodrug approach (11%). 

Opioids are presently the primary target drug class for abuse deterrent product development 
Over 75% of technology providers claim to be focused on developing tools to formulate safer and abuse proof versions of prescription pain medication. Other drug classes that represent likely candidates for tamper proofing include central nervous system (CNS) depressants and stimulants.

Over 8,000 patents have been filed / granted, since 2000
Of these, close to 5,000 patents related to abuse deterrent formulations and technologies were filed / granted in the US alone. Other key regions with significant intellectual capital include (in decreasing order of number of patents filed / granted) Australia, Europe, Canada, Mexico and China.

The partnership activity between drug and technology developers is anticipated to increase in the mid long term
Majority of the agreements (24%) established in the past were observed to have been focused on licensing and commercialization of abuse deterrent products. This was followed by agreements signed for the development of abuse deterrent formulations (22%), in the period 2013-2019 (till March). 

North America and Europe are anticipated to capture over 95% of the market share by 2030
The abuse deterrent formulation technologies market is anticipated to witness rapid growth over the next decade. Further, the market for technologies targeting opioids is expected to capture the majority share in the coming years.

To request a sample copy / brochure of this report, please visit this link 

Key Questions Answered
  • What are the key drug classes that can be targeted for development of abuse deterrent formulations?
  • What are the most popular types of abuse deterrence approaches? 
  • Who are the leading abuse deterrent technology providers in the market?
  • Which are the most popular abuse deterrent formulation technologies across players belonging to different peer groups?
  • What are the most popular types of partnership agreements in this domain?
  • How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the abuse deterrent formulation technologies market has been analyzed across the following segments:

  • Type of drug class 
    • Opioids
    • CNS Depressants
    • CNS Stimulants
  • Type of abuse deterrence approach
    • Physical / Chemical Barriers
    • Agonist / Antagonist Combinations
    • Aversion Approach 
    • Prodrug Approach
    • Abuse Deterrent Drug Delivery Systems 
  • Type of end product
    • Tablets
    • Capsules
    • Thin Films
    • Others
  • Key geographical regions 
    • North America
    • Europe
    • Asia Pacific and Rest of the World

The report features inputs from eminent industry stakeholders, according to whom abuse deterrent formulation technologies are promising alternatives for addressing the concerns associated with prescription drug abuse, specifically opioids. The report includes detailed transcripts of discussions held with the following experts:

  • Greg Sturmer (President and Chief Executive Officer, Elysium Therapeutics)
  • Aia Malik (Commercial Development Manager, Healthcare, Lucideon)

 
The research covers brief profiles of several companies (including those listed below); each profile features an overview and key highlights of the company, financial information (if available), a description of its abuse deterrent formulation technology(s), and the recent developments and future outlook.

  • Acura Pharmaceuticals
  • Altus Formulation
  • BioDelivery Sciences International
  • CIMA LABS
  • Elysium Therapeutics
  • Grünenthal
  • Intellipharmaceutics
  • Purdue Pharma
  • TITAN Pharmaceuticals

For additional details, please visit 
https://www.rootsanalysis.com/reports/view_document/abuse-deterrent-formulation-technologies-market-2019-2030/263.html

or email sales@rootsanalysis.com

You may also be interested in the following titles: 

  1. Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030
  2. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry

-->